Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

25.56 -1.73

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

25.18

Maximum

25.94

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+57.63% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

826M

2.9B

Előző nyitás

27.29

Előző zárás

25.56

Hangulat hírek alapján

By Acuity

50%

50%

150 / 340 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 23:46 UTC

News

PG&E Corp shares are lower in after-market hours despite announcing an expansion of its Vehicle to Everything program and analysts' fair value estimate of $22.59.

2026. aug. 24. 23:46 UTC

News

DA Davidson initiated coverage of Vulcan Materials Co with a Buy rating. Shares traded higher in after-market hours following Monday's close of $276.04.

2026. aug. 24. 23:46 UTC

News

Jack Henry & Associates appoints Richard N. Preece to its Board of Directors, effective August 20, 2026. Shares are higher in after-market trading.

2026. aug. 24. 23:46 UTC

News

Parker-Hannifin Corp filed a mixed securities shelf to raise capital. Shares advanced in after-market trading, continuing a trend of higher daily closes.

2026. aug. 24. 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

2026. aug. 24. 23:26 UTC

News

National Beverage Corp's shares are lower in after-market hours, despite recent strength and five consecutive higher closes, amid geopolitical concerns affecting market sentiment.

2026. aug. 24. 23:21 UTC

News

USD/HKD is trading lower, impacted by a stronger U.S. Dollar and economic pressures from new sanctions on Iran. Limited fluctuations persist in the market.

2026. aug. 24. 23:16 UTC

News

Trade Desk Inc's stock fell in after-hours trading following a prospectus filing for a mixed shelf offering of various securities. The company holds $1.12 billion in cash.

2026. aug. 24. 23:16 UTC

News

Coinbase Global Inc shares declined in after-market trading following the company's integration of Chainlink for real-time pricing of tokenized stocks on Base.

2026. aug. 24. 23:16 UTC

News

Diamondback Energy shares are lower in after-market hours amid concerns from CEO Van't Hof's recent insider selling of 10,000 shares at $214.66 each.

2026. aug. 24. 23:11 UTC

News

Nasdaq Inc shares are trading lower in after-market hours, reflecting broader market declines driven by weakness in technology stocks and geopolitical tensions.

2026. aug. 24. 23:11 UTC

News

Copart Inc shares are lower in after-market hours, reflecting unusual volatility amid broader market concerns over geopolitical tensions and economic disruptions.

2026. aug. 24. 23:06 UTC

Event
News

Gilead Sciences gains after European approval for Trodelvy and raises 2026 sales guidance to $30.1–$30.4 billion, reflecting strong performance in HIV and oncology.

2026. aug. 24. 23:01 UTC

Social Media
News

Re/Max Holdings Inc. announced a $450 million share repurchase authorization, contributing to a higher trading performance during after-market hours.

2026. aug. 24. 23:01 UTC

News

Grand Canyon Education shares declined in after-market hours following CFO Daniel E. Bachus's placement on paid administrative leave amid an ongoing investigation.

2026. aug. 24. 23:01 UTC

News

Herc Holdings shares rise in after-market trading following director Erik Olsson's $503K purchase of 3.1K shares, signaling potential confidence in the company.

2026. aug. 24. 23:01 UTC

News

Tyson Foods announced a $1 million commitment to the Harvest to Hallways initiative, enhancing childhood nutrition and food access, contributing to positive sentiment.

2026. aug. 24. 23:01 UTC

News

Oshkosh shares are higher in after-market trading following praise from Secretary of War Pete Hegseth for the company's defense manufacturing capabilities and tactical vehicles.

2026. aug. 24. 23:01 UTC

News

Vistra Corp shares rose in after-market trading after CEO James Burke bought 2,000 shares for $270,000, increasing his total ownership to 1.235 million shares.

2026. aug. 24. 22:51 UTC

News
Social Media

Boeing Co received a $131.23 billion contract for the F-15 Eagle Crest, with shares trading higher in after-market hours following the announcement.

2026. aug. 24. 22:16 UTC

News

A federal court upheld an $83.4 million award against Guardant Health for patent infringement, though shares are trading higher in after-market hours.

2026. aug. 24. 22:16 UTC

News

Kenneth S. Courtis bought $3.2 million in Alpha Metallurgical Resources shares, contributing to modest after-market gains following recent insider purchases.

2026. aug. 24. 22:06 UTC

News

Peabody Energy shares are lower in after-market hours following a class action lawsuit alleging misleading statements about its Centurion mine operations.

2026. aug. 24. 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

2026. aug. 24. 21:41 UTC

News

Franklin Resources announces cash distributions for ETFs, with payments set for September 2026. Shares are trading higher in after-market hours following the news.

2026. aug. 24. 21:02 UTC

News

DA Davidson initiated coverage of Advanced Drainage Systems with a Buy rating. Shares rose in after-market trading, closing at $143.73.

2026. aug. 24. 21:01 UTC

News

Owens Corning shares rise in after-market trading following a Buy rating from DA Davidson analyst Garik Shmois. The stock closed at $148.06.

2026. aug. 24. 20:07 UTC

Social Media
News

Uber Technologies has partnered with Zoomcar to offer intercity ride options in India. Shares are higher as the initiative launches in major cities.

2026. aug. 24. 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA Corp's stock is lower amid negative sentiment from a senior manager's indictment for alleged AI chip smuggling and rising costs for customers.

2026. aug. 24. 20:07 UTC

News

Impinj Inc shares are lower amid pressure in the Semiconductors sector and concerns over licensing revenue from NXP. Adjusted EBITDA margin is 15%.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

57.63% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 41 USD  57.63%

Magas 45 USD

Alacsony 37 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

2

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat